Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.17 EUR Market Closed
Market Cap: 101.1m EUR
Have any thoughts about
Heidelberg Pharma AG?
Write Note

Wall Street
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.

Lowest
Price Target
11.41 EUR
426% Upside
Average
Price Target
11.53 EUR
431% Upside
Highest
Price Target
11.87 EUR
447% Upside
Heidelberg Pharma AG Competitors:
Price Targets
BMRN
Biomarin Pharmaceutical Inc
55% Upside
SKYE
Skye Bioscience Inc
343% Upside
ALEC
Alector Inc
246% Upside
IMAB
I-Mab
646% Upside
BCAB
Bioatla Inc
525% Upside
4974
Takara Bio Inc
46% Upside
ALKS
Alkermes Plc
20% Upside
300896
Imeik Technology Development Co Ltd
39% Upside

Revenue
Forecast

Revenue Estimate
Heidelberg Pharma AG

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 3 years is 10%.

33%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HPHA's stock price target?
Price Target
11.53 EUR

According to Wall Street analysts, the average 1-year price target for HPHA is 11.53 EUR with a low forecast of 11.41 EUR and a high forecast of 11.87 EUR.

What is Heidelberg Pharma AG's Revenue forecast?
Projected CAGR
10%

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 3 years is 10%.

Back to Top